Literature DB >> 24928553

Vaccination in the elderly: what can be recommended?

Pierre-Olivier Lang1, Richard Aspinall.   

Abstract

The age-associated increased susceptibility to infectious disease would suggest that vaccination should be a route to promote healthy aging and keep our seniors autonomous and independent. While vaccination represents a cost-effective and efficient strategy at community level, the ability of the immune system to mount a protective immune response is still unpredictable at the level of the individual. Thus, at a similar age, some individuals, including the elderly, might still be 'good' responders while some other, even younger, would definitely fail to mount a protective response. In this review, the current burden of vaccine-preventable diseases in the aging and aged population will be detailed with the aim to identify the ideal vaccine candidates over the age of 50 years. This article will conclude with potential strategies to reduce, as best as possible, this burden and the imperative need to overcome barriers in extending current vaccine coverage towards to a lifelong vaccine schedule.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24928553     DOI: 10.1007/s40266-014-0193-1

Source DB:  PubMed          Journal:  Drugs Aging        ISSN: 1170-229X            Impact factor:   3.923


  186 in total

1.  Impact of respiratory virus infections on persons with chronic underlying conditions.

Authors:  W P Glezen; S B Greenberg; R L Atmar; P A Piedra; R B Couch
Journal:  JAMA       Date:  2000-01-26       Impact factor: 56.272

2.  A global prescription for adult immunization: time is catching up with us.

Authors:  Gregory A Poland; Joël Belmin; Joanne Langley; Jean-Pierre Michel; Pierre Van Damme; Sabine Wicker
Journal:  Vaccine       Date:  2010-10-18       Impact factor: 3.641

3.  Phase 1 trial of a 13-valent pneumococcal conjugate vaccine in healthy adults.

Authors:  Daniel A Scott; Steven F Komjathy; Branda T Hu; Sherryl Baker; Lois A Supan; Carol A Monahan; William Gruber; George R Siber; Stephen P Lockhart
Journal:  Vaccine       Date:  2007-06-26       Impact factor: 3.641

4.  23-valent pneumococcal polysaccharide vaccine. WHO position paper.

Authors: 
Journal:  Wkly Epidemiol Rec       Date:  2008-10-17

5.  Influenza and the winter increase in mortality in the United States, 1959-1999.

Authors:  Thomas A Reichert; Lone Simonsen; Ashutosh Sharma; Scott A Pardo; David S Fedson; Mark A Miller
Journal:  Am J Epidemiol       Date:  2004-09-01       Impact factor: 4.897

6.  A dose-response study of a live attenuated varicella-zoster virus (Oka strain) vaccine administered to adults 55 years of age and older.

Authors:  R Berger; E Trannoy; G Holländer; F Bailleux; C Rudin; H Creusvaux
Journal:  J Infect Dis       Date:  1998-11       Impact factor: 5.226

7.  Revaccination with the 23-valent pneumococcal polysaccharide vaccine in middle-aged and elderly persons previously treated for pneumonia.

Authors:  Jan Törling; Jonas Hedlund; Helle Bossen Konradsen; Ake Ortqvist
Journal:  Vaccine       Date:  2003-12-08       Impact factor: 3.641

8.  Causes of death and characteristics of decedents with viral hepatitis, United States, 2010.

Authors:  Kathleen N Ly; Jian Xing; R Monina Klevens; Ruth B Jiles; Scott D Holmberg
Journal:  Clin Infect Dis       Date:  2013-09-24       Impact factor: 9.079

9.  The Avalanche is Coming … And Just Now It's Starting to Snow.

Authors:  Richard Aspinall; Pierre Olivier Lang
Journal:  Front Immunol       Date:  2013-06-25       Impact factor: 7.561

Review 10.  Vaccine herd effect.

Authors:  Tae Hyong Kim; Jennie Johnstone; Mark Loeb
Journal:  Scand J Infect Dis       Date:  2011-05-23
View more
  6 in total

Review 1.  Vaccination for quality of life: herpes-zoster vaccines.

Authors:  Pierre-Olivier Lang; Richard Aspinall
Journal:  Aging Clin Exp Res       Date:  2019-10-23       Impact factor: 3.636

Review 2.  Recommended immunization schedules for adults: Clinical practice guidelines by the Escmid Vaccine Study Group (EVASG), European Geriatric Medicine Society (EUGMS) and the World Association for Infectious Diseases and Immunological Disorders (WAidid).

Authors:  Susanna Esposito; Paolo Bonanni; Stefania Maggi; Litjan Tan; Filippo Ansaldi; Pier Luigi Lopalco; Ron Dagan; Jean-Pierre Michel; Pierre van Damme; Jacques Gaillat; Roman Prymula; Timo Vesikari; Cristina Mussini; Uwe Frank; Albert Osterhaus; Lucia Pastore Celentano; Marta Rossi; Valentina Guercio; Gaetan Gavazzi
Journal:  Hum Vaccin Immunother       Date:  2016-05-02       Impact factor: 3.452

Review 3.  Can we translate vitamin D immunomodulating effect on innate and adaptive immunity to vaccine response?

Authors:  Pierre Olivier Lang; Richard Aspinall
Journal:  Nutrients       Date:  2015-03-20       Impact factor: 5.717

4.  Herpes zoster vaccine: A health economic evaluation for Switzerland.

Authors:  Patricia R Blank; Zanfina Ademi; Xiaoyan Lu; Thomas D Szucs; Matthias Schwenkglenks
Journal:  Hum Vaccin Immunother       Date:  2017-05-08       Impact factor: 3.452

5.  Fighting against a protean enemy: immunosenescence, vaccines, and healthy aging.

Authors:  Giuseppe Del Giudice; Jörg J Goronzy; Beatrix Grubeck-Loebenstein; Paul-Henri Lambert; Tomas Mrkvan; Jeffrey J Stoddard; T Mark Doherty
Journal:  NPJ Aging Mech Dis       Date:  2017-12-21

Review 6.  Vaccination programs for older adults in an era of demographic change.

Authors:  T Mark Doherty; Mark P Connolly; Giuseppe Del Giudice; Johan Flamaing; Jorg J Goronzy; Beatrix Grubeck-Loebenstein; Paul-Henri Lambert; Stefania Maggi; Janet E McElhaney; Hideaki Nagai; William Schaffner; Ruprecht Schmidt-Ott; Edward Walsh; Alberta Di Pasquale
Journal:  Eur Geriatr Med       Date:  2018-03-19       Impact factor: 1.710

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.